153 related articles for article (PubMed ID: 21495973)
1. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients.
de Leon J
Curr Drug Metab; 2011 Sep; 12(7):635-46. PubMed ID: 21495973
[TBL] [Abstract][Full Text] [Related]
2. [Anticholinergic scales: Use in psychiatry and update of the anticholinergic impregnation scale].
Javelot H; Meyer G; Becker G; Post G; Runge V; Pospieszynski P; Schneiderlin T; Armand-Branger S; Michel B; Weiner L; Faria CGF; Drapier D; Fakra E; Fossati P; Haffen E; Yrondi A; Hingray C
Encephale; 2022 Jun; 48(3):313-324. PubMed ID: 34876278
[TBL] [Abstract][Full Text] [Related]
3. Pharmcokinetic and pharmacodynamic considerations for the anticholinergic burden scale of drugs.
Yamada S; Mochizuki M; Atobe K; Kato Y
Geriatr Gerontol Int; 2024 Mar; 24 Suppl 1():81-87. PubMed ID: 37872832
[TBL] [Abstract][Full Text] [Related]
4. Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients.
Toto S; Hefner G; Hahn M; Hiemke C; Roll SC; Wolff J; Klimke A
J Neural Transm (Vienna); 2021 Feb; 128(2):263-272. PubMed ID: 33439364
[TBL] [Abstract][Full Text] [Related]
5. [The adverse effects of anticholinergic drugs].
Iwaki H; Nomoto M
Brain Nerve; 2014 May; 66(5):551-60. PubMed ID: 24807371
[TBL] [Abstract][Full Text] [Related]
6. Anticholinergic drug burden in older people's brain - how well is it measured?
Kersten H; Wyller TB
Basic Clin Pharmacol Toxicol; 2014 Feb; 114(2):151-9. PubMed ID: 24112192
[TBL] [Abstract][Full Text] [Related]
7. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
Chengappa KN; Pollock BG; Parepally H; Levine J; Kirshner MA; Brar JS; Zoretich RA
J Clin Psychopharmacol; 2000 Jun; 20(3):311-6. PubMed ID: 10831017
[TBL] [Abstract][Full Text] [Related]
8. An anticholinergic burden score for German prescribers: score development.
Kiesel EK; Hopf YM; Drey M
BMC Geriatr; 2018 Oct; 18(1):239. PubMed ID: 30305048
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
Davis R; Wilde MI
CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.
Scheife R; Takeda M
Clin Ther; 2005 Feb; 27(2):144-53. PubMed ID: 15811477
[TBL] [Abstract][Full Text] [Related]
11. Anticholinergics: theoretical and clinical overview.
Nishtala PS; Salahudeen MS; Hilmer SN
Expert Opin Drug Saf; 2016 Jun; 15(6):753-68. PubMed ID: 26966981
[TBL] [Abstract][Full Text] [Related]
12. Managing drugs with anticholinergic activity.
Bishara D
Drug Ther Bull; 2023 Sep; 61(9):135-139. PubMed ID: 37648260
[TBL] [Abstract][Full Text] [Related]
13. Central Anticholinergic Adverse Effects and Their Measurement.
Lampela P; Paajanen T; Hartikainen S; Huupponen R
Drugs Aging; 2015 Dec; 32(12):963-74. PubMed ID: 26518014
[TBL] [Abstract][Full Text] [Related]
14. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
Kay GG; Granville LJ
Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
[TBL] [Abstract][Full Text] [Related]
15. Association between anticholinergic burden and anticholinergic adverse outcomes in the elderly: Pharmacological basis of their predictive value for adverse outcomes.
Lavrador M; Castel-Branco MM; Cabral AC; Veríssimo MT; Figueiredo IV; Fernandez-Llimos F
Pharmacol Res; 2021 Jan; 163():105306. PubMed ID: 33248197
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced cognitive impairment in the elderly.
Moore AR; O'Keeffe ST
Drugs Aging; 1999 Jul; 15(1):15-28. PubMed ID: 10459729
[TBL] [Abstract][Full Text] [Related]
17. Drugs with anticholinergic properties: a current perspective on use and safety.
Gerretsen P; Pollock BG
Expert Opin Drug Saf; 2011 Sep; 10(5):751-65. PubMed ID: 21635190
[TBL] [Abstract][Full Text] [Related]
18. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events.
Ness J; Hoth A; Barnett MJ; Shorr RI; Kaboli PJ
Am J Geriatr Pharmacother; 2006 Mar; 4(1):42-51. PubMed ID: 16730620
[TBL] [Abstract][Full Text] [Related]
19. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
Minzenberg MJ; Poole JH; Benton C; Vinogradov S
Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, risk factors and adverse outcomes of anticholinergic burden in patients with advanced chronic conditions at hospital admission.
Sevilla-Sánchez D; Molist-Brunet N; González-Bueno J; Solà-Bonada N; Espaulella-Panicot J; Codina-Jané C
Geriatr Gerontol Int; 2018 Aug; 18(8):1159-1165. PubMed ID: 29644803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
